Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Lemborexant Archives - The Pharma Times | Pharma & Health Care News Portal

Lemborexant

Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)

Tokyo, August 26, 2020: Eisai Co., Ltd. announced today that a total of 10 presentations including the latest data on…

4 years ago

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia

Tokyo, June 04, 2020: Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered…

4 years ago

Eisai to Present Latest Data on Lemborexant at World Sleep Congress

Tokyo September 21, 2019: Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being…

5 years ago

Eisai Buys Out Purdue Rights to End Collaboration

New Delhi, May 02, 2019: Eisai Co., Ltd. announces that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma…

5 years ago

Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting

New Delhi, April 25, 2019: Eisai Co., Ltd. has announced that the latest data on its dual orexin receptor antagonist…

5 years ago

Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia

New Delhi, March 14, 2019: Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue…

5 years ago

Eisai’s Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan

New Delhi, March 08, 2019: Eisai Co., Ltd. has announced that a marketing authorization application has been submitted in Japan for…

5 years ago

Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study

Tokyo, February 17, 2019: Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase…

5 years ago

Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder

At 43rd Annual Meeting of The Japan Society of Sleep Research At “Drug Discovery Research For Sleep Medicine” Symposium Tokyo,…

6 years ago